Rudkin Brian B.
Brian B. Rudkin / DR2 - CNRS
Research interests
Research Director at the CNRS within the Stem Cell and Brain Research Institute (SBRI), Inserm U1208, University of Lyon and Co-Founder, in 2009, of the Joint Laboratory on Neuropathogenesis along with Prof. Chonggang YUAN at East China Normal University (ECNU) in Shanghai, integrated into the Key Laboratory of Brain Functional Genomics at the ECNU in January 2014.
The main objective is the transfer of fundamental discoveries using small antibody mimetics called peptide aptamers, to potential patient benefit in the context of the StemGamE platform.
The present transfer focus: • neurodegenerative diseases - e.g. ALS (Amyotrophic Lateral Sclerosis - Maladie de Charcot) • stimulation of the immune response e.g. for adoptive cell therapy of certain cancers • enhancement of safety of the use of embryonic stem cell-derived cultures for potential therapeutic benefit.
Member of Platforms
Selected Publications of Brian B. Rudkin
Year |
Reference | Title | Authors | Journal | PUB MED | ||
|---|---|---|---|---|---|---|---|
| 1996 | 12(2):309-22 | Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells | Savatier P, Lapillonne H, van Grunsven LA, Rudkin BB, Samarut J | Oncogene | |||
| 1996 | 12(6):1347-56 | Effect of nerve growth factor on the expression of cell cycle regulatory proteins in PC12 cells: dissection of the neurotrophic response from the anti-mitogenic response | van Grunsven LA, Billon N, Savatier P, Thomas A, Urdiales JL, Rudkin BB | Oncogene | - | ||
| 1996 | 12(6):1347-56 | Effect of nerve growth factor on the expression of cell cycle regulatory proteins in PC12 cells: dissection of the neurotrophic response from the anti-mitogenic response | van Grunsven LA, Billon N, Savatier P, Thomas A, Urdiales JL, Rudkin BB | Oncogene | |||
| 1996 | 785:298-300 | Expression of Trk receptors during cartilage differentiation | Mitsiadis TA, Wroblewski J, Urdiales JL, Becker E, Martin-Zanca D, Rudkin BB, Lendahl U | Ann N Y Acad Sci | - | ||
| 1996 | 12(2):309-22 | Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells | Savatier P, Lapillonne H, van Grunsven LA, Rudkin BB, Samarut J | Oncogene | - | ||
| 1997 | 15(4):393-402 | Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain | Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M | Oncogene | - | ||
| 1997 | 14(3):265-75 | Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations | Rossel M, Pasini A, Chappuis S, Geneste O, Fournier L, Schuffenecker I, Takahashi M, van Grunsven LA, Urdiales JL, Rudkin BB, Lenoir GM, Billaud M | Oncogene | - | ||
| 1998 | 17(13):1663-72 | Human primitive neuroectodermal tumour cells behave as multipotent neural precursors in response to FGF2 | Derrington EA, Dufay N, Rudkin BB, Belin MF | Oncogene | - | ||
| 1998 | 16(7):825-32 | Specific TrkA survival signals interfere with different apoptotic pathways | Ulrich E, Duwel A, Kauffmann-Zeh A, Gilbert C, Lyon D, Rudkin BB, Evan G, Martin-Zanca D | Oncogene | - | ||
| 1998 | pp100 - 106. IOS Press, Amsterdam | Decision-Making in a cell: Proliferation, Differentiation, Apoptosis? | Rudkin BB, Evan GI, Martin-Zanca D | Cancer Research Supported under Biomed1 | - | ||